Analyst Rating Update on The Spectranetics Corporation (SPNC)

The Spectranetics Corporation (SPNC) : Zacks Investment Research ranks The Spectranetics Corporation (SPNC) as 3, which is a Hold recommendation. 7 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 9 research analysts is 1.44, which indicates as a Strong Buy.

The Spectranetics Corporation (SPNC) : The most positive equity analysts on The Spectranetics Corporation (SPNC) expects the shares to touch $28, whereas, the least positive believes that the stock will trade at $14 in the short term. The company is covered by 10 Wall Street Brokerage Firms. The average price target for shares are $23.3 with an expected fluctuation of $4.42 from the mean.

For the current week, the company shares have a recommendation consensus of Buy.


The Spectranetics Corporation (NASDAQ:SPNC): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $23.77 and $23.46 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $24.50. The buying momentum continued till the end and the stock did not give up its gains. It closed at $23.67, notching a gain of 2.51% for the day. The total traded volume was 1,108,037 . The stock had closed at $23.09 on the previous day.

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Companys products are used to treat arterial blockages in the heart and legs and to remove pacemaker and defibrillator cardiac leads. The Company offers excimer laser system known as the CVX-300. Its Vascular Intervention business unit includes a range of peripheral and cardiac laser catheters for ablation of blockages in arteries above and below the knee (peripheral atherectomy) and within coronary arteries (coronary atherectomy); support catheters to facilitate crossing of coronary and peripheral arterial blockages (crossing solutions); and thrombectomy catheters for the removal of thrombus (thrombus management). The Companys Lead Management business unit includes excimer laser sheaths, non-laser sheaths and cardiac lead management accessories.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.